Analyst Price Targets — APGE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 17, 2026 8:06 pm | Danielle Brill | Truist Financial | $83.00 | $69.85 | StreetInsider | Truist Securities Starts Apogee Therapeutics Inc (APGE) at Hold |
| February 2, 2026 12:41 pm | Akash Tewari | Jefferies | $95.00 | $65.99 | StreetInsider | Apogee Therapeutics Inc (APGE) PT Lowered to $95 at Jefferies |
| January 22, 2026 10:18 am | — | RBC Capital | $83.00 | $81.91 | TheFly | Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital |
| January 7, 2026 2:08 pm | — | Craig-Hallum | $116.00 | $78.20 | TheFly | Apogee Therapeutics price target raised to $116 from $109 at Craig-Hallum |
| January 6, 2026 3:19 pm | — | BTIG | $137.00 | $76.78 | TheFly | Apogee Therapeutics price target raised to $137 from $128 at BTIG |
| January 6, 2026 2:25 pm | — | Stifel Nicolaus | $133.00 | $76.34 | TheFly | Apogee Therapeutics price target raised to $133 from $95 at Stifel |
| December 16, 2025 9:20 pm | — | Stephens | $95.00 | $74.78 | TheFly | Apogee Therapeutics initiated with an Overweight at Stephens |
| December 9, 2025 10:59 pm | — | Deutsche Bank | $103.00 | $74.75 | TheFly | Apogee Therapeutics initiated with a Buy at Deutsche Bank |
| November 3, 2025 12:41 pm | — | Craig-Hallum | $109.00 | $56.63 | TheFly | Apogee Therapeutics initiated with a Buy at Craig-Hallum |
| September 25, 2025 9:20 am | — | RBC Capital | $60.00 | $37.52 | TheFly | Apogee Therapeutics initiated with an Outperform at RBC Capital |
Latest News for APGE
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report)'s share price hit a new 52-week high on Wednesday. The stock traded as high as $89.63 and last traded at $88.47, with a volume of 559815 shares changing hands. The stock had previously closed at $86.74. Analysts Set New Price Targets Several analysts have recently weighed
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $82.58, for a total transaction of $1,651,600.00. Following the transaction, the chief executive officer owned 1,132,987 shares in
Aberdeen Group plc lessened its stake in Apogee Therapeutics Inc. (NASDAQ: APGE) by 34.1% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,103 shares of the company's stock after selling 18,657 shares during the quarter. Aberdeen Group plc owned approximately 0.05% of Apogee Therapeutics
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including…
The CEO of Apogee Therapeutics reported selling 20,000 shares of the company for approximately $1.50 million on March 11, 2026. This disposition represented 1.71% of Henderson's direct holdings at the time of the transaction, as reported in the Form 4.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for APGE.
U.S. House Trading
No House trades found for APGE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.